$0.79
+0.08 (+10.53%)
Open$0.67
Previous Close$0.71
Day High$0.83
Day Low$0.64
52W High$10.93
52W Low$6.81
Volume—
Avg Volume517.5K
Market Cap5.75M
P/E Ratio21.85
EPS$0.37
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,212.2% upside
Current
$0.79
$0.79
Target
$10.33
$10.33
$6.34
$10.33 avg
$12.82
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.14M | 2.03M | 2.27M |
| Net Income | 217.1K | 264.7K | 291.2K |
| Profit Margin | 10.1% | 13.0% | 12.9% |
| EBITDA | 334.0K | 340.0K | 365.4K |
| Free Cash Flow | 225.5K | 170.6K | 157.9K |
| Rev Growth | +23.7% | +5.3% | -4.1% |
| Debt/Equity | 1.01 | 0.93 | 0.78 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |